aspirin has been researched along with Fabry Disease in 4 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Fabry Disease: An X-linked inherited metabolic disease caused by a deficiency of lysosomal ALPHA-GALACTOSIDASE A. It is characterized by intralysosomal accumulation of globotriaosylceramide and other GLYCOSPHINGOLIPIDS in blood vessels throughout the body leading to multi-system complications including renal, cardiac, cerebrovascular, and skin disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fabry disease is caused by a deficiency of lysosomal alpha galactosidase and has a very large genotypic and phenotypic spectrum." | 1.72 | Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones. ( Allocca, M; Andreotti, G; Bosso, A; Cubellis, MV; Hay Mele, B; Liguori, L; Lukas, J; Monti, MC; Monticelli, M; Morretta, E, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Monticelli, M | 1 |
| Liguori, L | 1 |
| Allocca, M | 1 |
| Bosso, A | 1 |
| Andreotti, G | 1 |
| Lukas, J | 1 |
| Monti, MC | 1 |
| Morretta, E | 1 |
| Cubellis, MV | 1 |
| Hay Mele, B | 1 |
| Hollander, Z | 1 |
| Dai, DL | 1 |
| Putko, BN | 1 |
| Yogasundaram, H | 1 |
| Wilson-McManus, JE | 1 |
| Thompson, RB | 1 |
| Khan, A | 1 |
| West, ML | 1 |
| McManus, BM | 1 |
| Oudit, GY | 1 |
| Tchan, M | 1 |
| Sillence, D | 1 |
| Hughes, DA | 1 |
| Mehta, AB | 1 |
1 review available for aspirin and Fabry Disease
| Article | Year |
|---|---|
Vascular complications of Fabry disease: enzyme replacement and other therapies.
Topics: alpha-Galactosidase; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Blood Coagulati | 2005 |
3 other studies available for aspirin and Fabry Disease
| Article | Year |
|---|---|
Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones.
Topics: 1-Deoxynojirimycin; alpha-Galactosidase; Aspirin; Drug Repositioning; Fabry Disease; Humans; Lysosom | 2022 |
Gender-specific plasma proteomic biomarkers in patients with Anderson-Fabry disease.
Topics: Adolescent; Adult; Aged; alpha-Galactosidase; Aspirin; Biomarkers; Blood Proteins; Cerebrovascular D | 2015 |
Fabry disease and Factor V Leiden: a potent vascular risk combination.
Topics: Activated Protein C Resistance; alpha-Galactosidase; Aspirin; Atorvastatin; Coronary Stenosis; Defib | 2011 |